Stockscreener 앱 받기
0.6638
1.07%
-0.0072
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - PR Newswire
2026-01-18 | VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
Faruqi & Faruqi Investigates Vistagen Investors' Claims Ahead of March 2026 Deadline - Intellectia AI
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Short Interest in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Rises By 88.9% - Defense World
Vistagen Therapeutics (VTGN) Faces Class Action Over Misleading Trial Results, Stock Plummets 80% - Intellectia AI
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Vistagen Therapeutics Faces Class Action Lawsuit, Shareholders May Claim Compensation - Intellectia AI
Vistagen Therapeutics Faces Class Action Lawsuit for Misleading Investors on Drug Development - Intellectia AI
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire Inc.
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT - GlobeNewswire
About Us - FinancialContent
Vistagen Therapeutics Faces Class Action for Securities Fraud, Investors Can Claim Losses - Intellectia AI
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Vistagen Drug Trial Collapse Triggers Investor Lawsuit Wave - TipRanks
Vistagen Therapeutics (VTGN) Accused of Misleading Investors, Stock Plummets 80% - Intellectia AI
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - Weekly Voice
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Consensus PT from Analysts - Defense World
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
Vistagen Therapeutics, Inc. Unveils New Corporate Presentation - TradingView — Track All Markets
Vistagen fails in late-stage trial for social anxiety disorder therapy - MSN
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Insider Buying & Fast Exit Strategy with Risk Control - Улправда
VTGN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vistagen Therapeutics, Inc. investment - ACCESS Newswire
Vistagen appoints Nick Tressler as CFO - MSN
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
Aug Volume: Should I hold or sell Vistagen Therapeutics Inc stock in 2025July 2025 Intraday Action & Stepwise Trade Execution Plans - moha.gov.vn
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest - Defense World
Vistagen Therapeutics Inc (VTGN) deserves deeper analysis - uspostnews.com
ATTENTION VTGN SHAREHOLDERS: Investors who Lost Money on Vistagen Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
VTGN STOCK ALERT: Levi & Korsinsky Notifies Vistagen Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
William Blair downgrades Vistagen Therapeutics (VTGN) - MSN
Finance Watch: Vistagen To Cut Costs After Phase III Trial Failure - Citeline News & Insights
Levi & Korsinsky Announces an Investigation on Behalf of Vistagen Therapeutics, Inc. (VTGN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint - Investing.com Nigeria
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint By Investing.com - Investing.com South Africa
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD - TipRanks
Vistagen Therapeutics Reports Phase 3 Study Results - TradingView — Track All Markets
Vistagen Therapeutics, Inc. (VTGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Is Vistagen Therapeutics Stock Built to Withstand More Downside? - Trefis
How Vistagen Therapeutics Inc. stock reacts to bond yieldsWeekly Trade Analysis & Daily Growth Stock Investment Tips - Улправда
Can Vistagen Therapeutics Inc. stock sustain institutional interestJuly 2025 Selloffs & Reliable Momentum Entry Alerts - Улправда
Update Recap: Why retail investors pile into Vistagen Therapeutics Inc. stockPortfolio Performance Report & Accurate Entry and Exit Point Alerts - Улправда
Can Vistagen Therapeutics Inc. stock deliver consistent earnings growth2025 Sector Review & Momentum Based Trading Signals - Улправда
Can Vistagen Therapeutics Inc. stock beat analyst upgrades2025 Price Momentum & Precise Entry and Exit Recommendations - DonanımHaber
Why retail investors pile into Vistagen Therapeutics Inc. stockJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
4.73%
0.92%
자본화:
|
볼륨(24시간):